Trial Search Results

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Doppler Ultrasound
  • Device: Vantage 256 with C5-2v transducer

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Pathology-confirmed diagnosis of metastatic RCC

   - At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound
   imaging

   - Planned to be treated with VEGFR2 tyrosine kinase inhibitor plus immune checkpoint
   inhibitor

   - Written informed consent

Exclusion Criteria:

Any comorbid condition that, in the opinion of the treating provider or the Protocol
Directors, compromises the participant's ability to participate in the study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christian Hoerner, PhD
650-721-3206
Not Recruiting